We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Appearing before a federal appeals court Dec. 6, the FDA defended its policy of granting shared 180-day exclusivity periods to multiple generic firms that are first to challenge different patents on the same drug.